Developer docs
API playgroundTry for free, no card

Search company profiles

NJ Bio

Full company profile

uuid00026yy

Namestring
NJ Bio
Legal namestring
NJ Bio, Inc.
Websiteurl
njbio.com
Company typeenum
Private
Founded yearint
2019
Descriptiontext

NJ Bio, Inc. is a US-based contract research and manufacturing organization (CRO/CDMO) specializing in antibody-drug conjugates (ADCs), bioconjugation chemistry, and adjacent complex biotherapeutic modalities including oligonucleotides and mRNA. Founded in 2019 and headquartered in Princeton, New Jersey, the company operates GMP-compliant manufacturing facilities in Princeton and Bristol, Pennsylvania, plus a new oligonucleotide building block facility being built in Hyderabad, India. It functions as a wholly-owned subsidiary of Cohance Lifesciences (formerly Suven Pharma).

The company's core platform integrates bioconjugation, payload-linker synthesis, analytical and bioanalytical characterization (LC-MS and LBA), antibody production, and GMP clinical manufacturing within a single-site workflow spanning preclinical discovery through Phase I/II clinical supply. Proprietary technical assets include a linker-payload library of more than 2,000 combinations, a high-throughput screening platform evaluating 100+ monoclonal antibodies simultaneously, the AJICAP site-specific conjugation platform (integrated via partnership with Ajinomoto Bio-Pharma Services), validated payload classes (vedotin, emtansine, mafodotin, deruxtecan, govitecan), and OEB-5 high-containment capability for cytotoxic payloads. Translational research offerings include 200+ CDX and 1,000+ PDX oncology models.

NJ Bio generates revenue through fee-for-service CRO engagements (Express, Standard, and Custom Conjugation tiers), GMP CDMO manufacturing contracts with per-batch pricing, FTE (full-time equivalent) resource models, and integrated preclinical-to-clinical programs. Customers are primarily biopharmaceutical companies, early-stage biotechs, ADC platform companies, and oncology drug developers, engaged via "Request a Quote" custom pricing with no publicly disclosed rate cards. The go-to-market is enterprise direct sales with multi-year contracts.

Short descriptiontext

NJ Bio is a US-based CRO/CDMO specializing in antibody-drug conjugates, bioconjugation, and GMP clinical manufacturing, serving biopharmaceutical companies, early-stage biotechs, and ADC platform developers from discovery through Phase I/II clinical supply.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersPrinceton, United States
HQ citystring
Princeton
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
antibody-drug conjugate services, bioconjugation CRO, ADC manufacturing CDMO, payload-linker synthesis, oligonucleotide manufacturing
Industry4 codes
PRIMARYHLAGABAC
Biologics (mAbs/Recombinant Proteins) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAK
Clinical Trial Material (CTM) Manufacturing & Supply CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAF
mRNA/LNP & Nucleic Acid Therapeutics CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Services-Commercial Physical & Biological Research8731
Product category
Contract Research and Manufacturing Services (CRO/CDMO) for Biotherapeutics
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model4 records
1Contract Research Services (CRO)
TypeProfessional Services
Description

Fee-for-service research engagements covering ADC discovery, bioconjugation, analytical services, and translational research. Customers engage project-based with defined scopes, timelines, and deliverables. Service tiers include Express Conjugation (rapid screening), Standard Conjugation (preclinical), and Custom Conjugation (optimization).

njbio.com
2Contract Manufacturing Services (CDMO)
TypeManaged Services
Description

GMP manufacturing services for ADC drug substance, payload-linkers, mRNA, and oligonucleotides supporting Phase I and Phase II clinical trials. Manufacturing includes process development, scale-up, and analytical characterization. Revenue generated through batch manufacturing contracts with per-batch pricing.

njbio.com
3Translational Research Services
TypeProfessional Services
Description

In vivo and in vitro preclinical studies including xenograft models, PK/PD studies, and IND-enabling studies. Billed as standalone projects or integrated into larger drug development programs.

njbio.com
4FTE (Full-Time Equivalent) Models
TypeProfessional Services
Description

Flexible resource allocation model where dedicated scientific team members are assigned to client projects, allowing scalable engagement based on project complexity and duration.

njbio.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Infrastructure, Operations, Technology or R&D, Marketing or Sales, Supply Chain
Pricing details1 tier
1Custom Project-Based Pricing
ModelOtherBilling cadenceMulti-year contract
Notes

All services are quote-based with no published pricing. Projects are scoped individually based on service type (Express/Standard/Custom Conjugation), scale requirements, timeline, and technical complexity. GMP manufacturing priced per batch with factors including scale, potency classification, and analytical requirements.

njbio.com
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

NJ Bio is an integrated CRO/CDMO providing contract chemistry and biology services for antibody-drug conjugate (ADC), bioconjugate, oligonucleotide, and mRNA development. Its offerings span bioconjugation chemistry, payload-linker design and synthesis, high-throughput antibody screening, GMP clinical manufacturing for Phase I/II trials, bioanalytical characterization, and in vivo/in vitro translational research with oncology xenograft and PDX models. The company delivers these services to biopharmaceutical and biotechnology clients from co-located R&D and GMP facilities in Princeton, NJ and Bristol, PA.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Rapid ADC screening with high-throughput evaluation of 100+ monoclonal antibodies simultaneously
+2 more records
Product overview1 text field

NJ Bio is an integrated chemistry service provider and Contract Development and Manufacturing Organization (CRO/CDMO) specializing in complex biotherapeutics. The company operates as a single-site integrated platform offering multiple interconnected services: ADC Services (the core offering) encompasses bioconjugation, payload-linker development, antibody production, and GMP manufacturing; Manufacturing and CDMO Services provides clinical manufacturing capabilities for ADCs, mRNA, oligonucleotides, and antibody-oligonucleotide conjugates; Bioconjugation Services enables chemical conjugation across proteins, peptides, and oligonucleotides; Payloads and Linkers supplies validated, custom, and novel linker-payload combinations; Translational Research Services offers preclinical in vivo/in vitro studies and IND-enabling support; Bioanalytical Services provides LC-MS and LBA-based analysis; Oligonucleotide Services handles custom synthesis and manufacturing; and mRNA Services supports IVT mRNA synthesis and modification. The portfolio is unified by shared chemistry expertise, integrated workflows, and co-located R&D and manufacturing facilities in Princeton, NJ and Bristol, PA.

Product and service18 records
1ADC Services
CategoryADC Contract Research Services
Description

Comprehensive contract research services for antibody-drug conjugate development spanning early-stage research through IND-enabling studies. Combines bioconjugation, payload-linker synthesis, antibody production, translational research, screening platforms, analytical characterization, and GMP manufacturing for Phase I and II clinical trials. Targeted at biopharmaceutical and biotech developers of ADC therapeutics.

2Manufacturing and CDMO Services
CategoryContract Development and Manufacturing (CDMO)
Description

GMP clinical manufacturing services for ADCs, complex bioconjugates, mRNA, oligonucleotides, antibody-oligonucleotide conjugates, and linker payloads. Includes purpose-built manufacturing suites for Phase 1 and Phase 2 clinical trial materials using single-use technology. Designed for biopharmaceutical clients requiring cGMP-compliant production for early-stage clinical trials.

3Bioconjugation Services
CategoryBioconjugation Chemistry Services
Description

Chemical conjugation services for coupling biomolecules (antibodies, proteins, peptides, oligonucleotides) with various chemical entities. Offers three engagement tiers: Express Conjugation for rapid ADC screening, Standard Conjugation for preclinical studies, and Custom Conjugation for clinical development optimization. Utilizes diverse chemistries including lysine- and cysteine-based modifications, affinity-based conjugation, oxime and biorthogonal chemistries, glycan remodeling, transglutaminase-based methods, non-natural amino acid incorporation, click chemistry, and enzyme-assisted conjugation.

4Payloads and Linkers
CategoryPayload-Linker Manufacturing Services
Description

Design, synthesis, and GMP manufacturing of chemical payload-linkers for ADCs. Includes clinically validated combinations (MC-VCP-MMAE vedotin, SMCC-DM1 emtansine, SPDB-DM4), custom payloads, and novel linker-payload development. Capabilities include handling OEB-5 materials (OEL <10 ng/m³) and scaling from milligrams to tens of kilograms. Targets ADC developers requiring cytotoxic payloads such as auristatins, maytansinoids, duocarmycins, PBD dimers, camptothecins, and IGNs.

5Translational Research Services
CategoryTranslational and Preclinical Research Services
Description

Preclinical research services bridging discovery and clinical applications for oncology drug developers. Includes CDX models with over 200 authenticated human cancer cell lines, patient-derived xenograft (PDX) models with over 1,000 fully validated models spanning multiple disease indications, immuno-oncology studies, humanized mouse models, PK/PD studies, in vitro studies, IND-enabling research, and organoid/spheroid studies. Designed to support preclinical-to-clinical translation for oncology therapeutics.

6Bioanalytical Services
CategoryBioanalytical Characterization Services
Description

Bioanalysis for ADCs and bioconjugates using Ligand Binding Assays (LBA/ELISA), Liquid Chromatography-Mass Spectrometry (LC-MS), and hybrid LBA-LC-MS platforms. Services include PK analysis, drug-to-antibody ratio (DAR) determination, free payload quantification, immunogenicity assessment, and metabolite profiling. Targeted at developers requiring sensitive quantification and biotransformation characterization of ADC and bioconjugate drug candidates.

7Oligonucleotide Services
CategoryOligonucleotide Synthesis and Manufacturing
Description

Custom oligonucleotide synthesis and manufacturing using Phosphoramidite solid-phase synthesis. Services include DNA/RNA synthesis, chemical modifications (phosphorothioate, 2' modifications, LNA, PNA), conjugation with biomolecules, and GMP manufacturing from research-grade to clinical-grade (Phase I/II). Targeted at developers of oligonucleotide-based therapeutics, including antisense oligos, siRNA, aptamers, and antibody-oligonucleotide conjugates.

8mRNA Services
CategorymRNA Synthesis and Manufacturing
Description

Custom mRNA synthesis and manufacturing via in vitro transcription (IVT). Services include linearized plasmid transcription, modified NTP synthesis (natural and unnatural), capping strategies (ARCA, mCAP), poly(A) tailing, purification, and analytical characterization. Available at scales from milligram to multigram (up to 20g). Targeted at mRNA therapeutic and vaccine developers requiring research-grade through clinical-grade material.

9High-Throughput Screening Bioconjugation
CategoryHigh-Throughput Screening Services
Description

High-throughput bioconjugation screening platform enabling rapid evaluation of over 100 monoclonal antibodies simultaneously to identify those best suited for ADC and bioconjugate development. Provides developability screening to support rational candidate selection. Targeted at ADC developers seeking efficient antibody screening prior to lead optimization.

10BioNMR Services
CategoryAnalytical Characterization Services
Description

BioNMR spectroscopy services for drug discovery and structural characterization. Supports structural elucidation of biologics, bioconjugates, and small molecules, providing analytical insight into therapeutic candidates during development. Targeted at biopharmaceutical researchers requiring structural and conformational characterization of drug candidates.

11Protein Degraders Services
CategoryTargeted Protein Degradation Chemistry Services
Description

Chemistry services for targeted protein degraders including PROTAC and related molecular glue degrader modalities. Supports design, synthesis, and characterization of protein degrader conjugates and bifunctional molecules. Targeted at drug developers pursuing targeted protein degradation as a therapeutic modality.

12Medicinal Chemistry Services
CategoryMedicinal Chemistry Services
Description

Medicinal chemistry services for small molecule drug discovery. Includes analog synthesis, structure-activity relationship (SAR) studies, lead optimization, and custom synthesis to support hit-to-lead and lead optimization campaigns. Targeted at pharmaceutical and biotech researchers pursuing small molecule therapeutics.

13Custom Synthesis of Small Molecules
CategoryCustom Synthesis Services
Description

Custom synthesis of small molecules from milligram to multi-kilogram scale. Includes reference standards, building blocks, intermediates, and bespoke compounds for research and preclinical use. Targeted at pharmaceutical and biotech researchers requiring specialized chemical synthesis not available through standard catalogs.

14Synthesis of Nucleotides
CategoryNucleotide Synthesis Services
Description

Custom synthesis of nucleotides including phosphoramidite building blocks, modified nucleotides, and oligonucleotide precursors. Supports oligonucleotide therapeutics manufacturing and ADC linker chemistry development. Targeted at developers of oligonucleotide-based drugs and ADC linker chemistries requiring specialized nucleotide inputs.

15Analytical Services
CategoryAnalytical Services
Description

Analytical services for ADCs, small molecules, and large molecules. Includes method development, method validation, release testing, and stability studies supporting discovery through clinical manufacturing. Targeted at biopharmaceutical developers requiring cGMP-compliant analytical characterization of drug substance and drug product.

16Antibody Production
CategoryAntibody Production Services
Description

Antibody production services including monoclonal antibody expression, purification, and characterization to support ADC and bioconjugate development programs. Targeted at ADC and bioconjugate developers requiring antibody materials for screening, conjugation, and preclinical evaluation.

17Cell-Based Functional Assays
CategoryFunctional Assay Services
Description

Cell-based functional assay services including cytotoxicity assays, potency assays, and mechanism-of-action studies. Supports biotherapeutic characterization and ADC efficacy evaluation in vitro. Targeted at biotherapeutic developers requiring functional characterization of antibody and ADC candidates.

18Combined Payload-Linker Manufacturing Services
CategoryIntegrated Payload-Linker Manufacturing
Description

Integrated payload-linker manufacturing combining payload synthesis and linker conjugation under a single service engagement. Streamlines the supply chain for ADC developers by delivering ready-to-use payload-linker intermediates. Targeted at ADC developers seeking simplified vendor management for payload-linker procurement.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-03-31
Description

Research collaboration to integrate AJICAP site-specific conjugation platform into NJ Bio's ADC discovery and development workflows. Partnership aims to enhance NJ Bio's capabilities in site-specific conjugation, supporting development of targeted therapeutics with emphasis on reducing development risks and improving project outcomes through conjugation precision.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-11-06
Description

Asset purchase and full integration of L2P Research Labs' services to expand NJ Bio's translational research offerings. Acquisition enhances capabilities in preclinical and early-phase clinical research, particularly in oncology, supporting more seamless progression from proof-of-concept to clinic.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

WuXi XDC is the leading pure-play ADC CDMO, providing end-to-end antibody, payload-linker and bioconjugation services from discovery through GMP manufacturing. It is the closest direct competitor to NJ Bio in target customers, service scope and ADC specialization.

TypeEmerging player
Description

Ajinomoto Bio-Pharma Services offers cGMP biologics manufacturing and the AJICAP site-specific conjugation platform, with which NJ Bio has a formal partnership. It is both a potential competitor and partner in the ADC technology space.

TypeBroad incumbent
Description

AGC Biologics provides biologics CDMO services including bioconjugation and antibody-related manufacturing. It serves biopharma clients at clinical and commercial scale, making it a broad incumbent competitor in the bioconjugate space.

TypeDirect peer
Description

Novasep offers CDMO services including highly potent API manufacturing and bioconjugation for ADC clients. Its specialization in cytotoxic payloads and complex chemistry makes it a direct comparator to NJ Bio.

TypeDirect peer
Description

Piramal operates an ADC CDMO business with payload-linker development and GMP manufacturing capacity. It targets the same biopharma and biotech customers with comparable ADC-centric service offerings.

TypeDirect peer
Description

Sterling Pharma Solutions is a CDMO specializing in API development and high-potency manufacturing with growing bioconjugation services. Its focus on complex small molecules and HPAPIs overlaps directly with NJ Bio's payload-linker work.

TypeDirect peer
Description

Carbogen Amcis specializes in highly potent API and payload-linker synthesis with GMP manufacturing, including OEB-5 containment for cytotoxic payloads. Its high-potency focus makes it a direct comparator to NJ Bio's payload-linker capability.

TypeEmerging player
Description

BioDuro is a CRO/CDMO offering drug discovery, development and manufacturing services including ADC-related chemistry. It serves similar biotech customers but with broader small-molecule emphasis rather than ADC specialization.

TypeBroad incumbent
Description

Catalent offers bioconjugation and ADC development services across its global network of GMP facilities. It is a broad incumbent CDMO with overlap on ADC/bioconjugate work but competes from a much larger small-molecule and biologics platform.

TypeBroad incumbent
Description

Lonza is a global CDMO incumbent with a dedicated bioconjugates business unit offering ADC process development and GMP manufacturing. It competes with NJ Bio in clinical-stage ADC manufacturing but as part of a much broader services portfolio.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers6 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature8 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

NJ Bio

Contract Research and Manufacturing Services (CRO/CDMO) for Biotherapeuticsnjbio.com

NJ Bio is a US-based CRO/CDMO specializing in antibody-drug conjugates, bioconjugation, and GMP clinical manufacturing, serving biopharmaceutical companies, early-stage biotechs, and ADC platform developers from discovery through Phase I/II clinical supply.

What NJ Bio does

NJ Bio, Inc. is a US-based contract research and manufacturing organization (CRO/CDMO) specializing in antibody-drug conjugates (ADCs), bioconjugation chemistry, and adjacent complex biotherapeutic modalities including oligonucleotides and mRNA. Founded in 2019 and headquartered in Princeton, New Jersey, the company operates GMP-compliant manufacturing facilities in Princeton and Bristol, Pennsylvania, plus a new oligonucleotide building block facility being built in Hyderabad, India. It functions as a wholly-owned subsidiary of Cohance Lifesciences (formerly Suven Pharma).

The company's core platform integrates bioconjugation, payload-linker synthesis, analytical and bioanalytical characterization (LC-MS and LBA), antibody production, and GMP clinical manufacturing within a single-site workflow spanning preclinical discovery through Phase I/II clinical supply. Proprietary technical assets include a linker-payload library of more than 2,000 combinations, a high-throughput screening platform evaluating 100+ monoclonal antibodies simultaneously, the AJICAP site-specific conjugation platform (integrated via partnership with Ajinomoto Bio-Pharma Services), validated payload classes (vedotin, emtansine, mafodotin, deruxtecan, govitecan), and OEB-5 high-containment capability for cytotoxic payloads. Translational research offerings include 200+ CDX and 1,000+ PDX oncology models.

NJ Bio generates revenue through fee-for-service CRO engagements (Express, Standard, and Custom Conjugation tiers), GMP CDMO manufacturing contracts with per-batch pricing, FTE (full-time equivalent) resource models, and integrated preclinical-to-clinical programs. Customers are primarily biopharmaceutical companies, early-stage biotechs, ADC platform companies, and oncology drug developers, engaged via "Request a Quote" custom pricing with no publicly disclosed rate cards. The go-to-market is enterprise direct sales with multi-year contracts.

NJ Bio firmographics

Firmographics
Name
NJ Bio
Legal name
NJ Bio, Inc.
Website
https://njbio.com
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
101–250 employees
Short description
NJ Bio is a US-based CRO/CDMO specializing in antibody-drug conjugates, bioconjugation, and GMP clinical manufacturing, serving biopharmaceutical companies, early-stage biotechs, and ADC platform developers from discovery through Phase I/II clinical supply.
Ownership category
akta.pro rank

NJ Bio industry classification

Industry
Product category
Contract Research and Manufacturing Services (CRO/CDMO) for Biotherapeutics
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGABAC
Biologics (mAbs/Recombinant Proteins) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAK
Clinical Trial Material (CTM) Manufacturing & Supply CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAF
mRNA/LNP & Nucleic Acid Therapeutics CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)

Keywords

  • Antibody-drug conjugate services
  • Bioconjugation CRO
  • ADC manufacturing CDMO
  • Payload-linker synthesis
  • Oligonucleotide manufacturing

Where NJ Bio is headquartered

Location

Headquarters

HQ city
Princeton
HQ country
United States
HQ region
North America

Offices3 records

Markets served

NJ Bio business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Infrastructure, Operations, Technology or R&D, Marketing or Sales, Supply Chain

Revenue model

  1. Contract Research Services (CRO): Fee-for-service research engagements covering ADC discovery, bioconjugation, analytical services, and translational research. Customers engage project-based with defined scopes, timelines, and deliverables. Service tiers include Express Conjugation (rapid screening), Standard Conjugation (preclinical), and Custom Conjugation (optimization).
  2. Contract Manufacturing Services (CDMO): GMP manufacturing services for ADC drug substance, payload-linkers, mRNA, and oligonucleotides supporting Phase I and Phase II clinical trials. Manufacturing includes process development, scale-up, and analytical characterization. Revenue generated through batch manufacturing contracts with per-batch pricing.
  3. Translational Research Services: In vivo and in vitro preclinical studies including xenograft models, PK/PD studies, and IND-enabling studies. Billed as standalone projects or integrated into larger drug development programs.
  4. FTE (Full-Time Equivalent) Models: Flexible resource allocation model where dedicated scientific team members are assigned to client projects, allowing scalable engagement based on project complexity and duration.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractCustom Project-Based Pricing

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

NJ Bio product offering

Product offering

Core offering

NJ Bio is an integrated CRO/CDMO providing contract chemistry and biology services for antibody-drug conjugate (ADC), bioconjugate, oligonucleotide, and mRNA development. Its offerings span bioconjugation chemistry, payload-linker design and synthesis, high-throughput antibody screening, GMP clinical manufacturing for Phase I/II trials, bioanalytical characterization, and in vivo/in vitro translational research with oncology xenograft and PDX models. The company delivers these services to biopharmaceutical and biotechnology clients from co-located R&D and GMP facilities in Princeton, NJ and Bristol, PA.

Product overview

NJ Bio is an integrated chemistry service provider and Contract Development and Manufacturing Organization (CRO/CDMO) specializing in complex biotherapeutics. The company operates as a single-site integrated platform offering multiple interconnected services: ADC Services (the core offering) encompasses bioconjugation, payload-linker development, antibody production, and GMP manufacturing; Manufacturing and CDMO Services provides clinical manufacturing capabilities for ADCs, mRNA, oligonucleotides, and antibody-oligonucleotide conjugates; Bioconjugation Services enables chemical conjugation across proteins, peptides, and oligonucleotides; Payloads and Linkers supplies validated, custom, and novel linker-payload combinations; Translational Research Services offers preclinical in vivo/in vitro studies and IND-enabling support; Bioanalytical Services provides LC-MS and LBA-based analysis; Oligonucleotide Services handles custom synthesis and manufacturing; and mRNA Services supports IVT mRNA synthesis and modification. The portfolio is unified by shared chemistry expertise, integrated workflows, and co-located R&D and manufacturing facilities in Princeton, NJ and Bristol, PA.

Differentiator

Problem solved

Functional benefit

Products and services

  • ADC Services Comprehensive contract research services for antibody-drug conjugate development spanning early-stage research through IND-enabling studies. Combines bioconjugation, payload-linker synthesis, antibody production, translational research, screening platforms, analytical characterization, and GMP manufacturing for Phase I and II clinical trials. Targeted at biopharmaceutical and biotech developers of ADC therapeutics.
  • Manufacturing and CDMO Services GMP clinical manufacturing services for ADCs, complex bioconjugates, mRNA, oligonucleotides, antibody-oligonucleotide conjugates, and linker payloads. Includes purpose-built manufacturing suites for Phase 1 and Phase 2 clinical trial materials using single-use technology. Designed for biopharmaceutical clients requiring cGMP-compliant production for early-stage clinical trials.
  • Bioconjugation Services Chemical conjugation services for coupling biomolecules (antibodies, proteins, peptides, oligonucleotides) with various chemical entities. Offers three engagement tiers: Express Conjugation for rapid ADC screening, Standard Conjugation for preclinical studies, and Custom Conjugation for clinical development optimization. Utilizes diverse chemistries including lysine- and cysteine-based modifications, affinity-based conjugation, oxime and biorthogonal chemistries, glycan remodeling, transglutaminase-based methods, non-natural amino acid incorporation, click chemistry, and enzyme-assisted conjugation.
  • Payloads and Linkers Design, synthesis, and GMP manufacturing of chemical payload-linkers for ADCs. Includes clinically validated combinations (MC-VCP-MMAE vedotin, SMCC-DM1 emtansine, SPDB-DM4), custom payloads, and novel linker-payload development. Capabilities include handling OEB-5 materials (OEL <10 ng/m³) and scaling from milligrams to tens of kilograms. Targets ADC developers requiring cytotoxic payloads such as auristatins, maytansinoids, duocarmycins, PBD dimers, camptothecins, and IGNs.
  • Translational Research Services Preclinical research services bridging discovery and clinical applications for oncology drug developers. Includes CDX models with over 200 authenticated human cancer cell lines, patient-derived xenograft (PDX) models with over 1,000 fully validated models spanning multiple disease indications, immuno-oncology studies, humanized mouse models, PK/PD studies, in vitro studies, IND-enabling research, and organoid/spheroid studies. Designed to support preclinical-to-clinical translation for oncology therapeutics.
  • Bioanalytical Services Bioanalysis for ADCs and bioconjugates using Ligand Binding Assays (LBA/ELISA), Liquid Chromatography-Mass Spectrometry (LC-MS), and hybrid LBA-LC-MS platforms. Services include PK analysis, drug-to-antibody ratio (DAR) determination, free payload quantification, immunogenicity assessment, and metabolite profiling. Targeted at developers requiring sensitive quantification and biotransformation characterization of ADC and bioconjugate drug candidates.
  • Oligonucleotide Services Custom oligonucleotide synthesis and manufacturing using Phosphoramidite solid-phase synthesis. Services include DNA/RNA synthesis, chemical modifications (phosphorothioate, 2' modifications, LNA, PNA), conjugation with biomolecules, and GMP manufacturing from research-grade to clinical-grade (Phase I/II). Targeted at developers of oligonucleotide-based therapeutics, including antisense oligos, siRNA, aptamers, and antibody-oligonucleotide conjugates.
  • mRNA Services Custom mRNA synthesis and manufacturing via in vitro transcription (IVT). Services include linearized plasmid transcription, modified NTP synthesis (natural and unnatural), capping strategies (ARCA, mCAP), poly(A) tailing, purification, and analytical characterization. Available at scales from milligram to multigram (up to 20g). Targeted at mRNA therapeutic and vaccine developers requiring research-grade through clinical-grade material.
  • High-Throughput Screening Bioconjugation High-throughput bioconjugation screening platform enabling rapid evaluation of over 100 monoclonal antibodies simultaneously to identify those best suited for ADC and bioconjugate development. Provides developability screening to support rational candidate selection. Targeted at ADC developers seeking efficient antibody screening prior to lead optimization.
  • BioNMR Services BioNMR spectroscopy services for drug discovery and structural characterization. Supports structural elucidation of biologics, bioconjugates, and small molecules, providing analytical insight into therapeutic candidates during development. Targeted at biopharmaceutical researchers requiring structural and conformational characterization of drug candidates.
  • Protein Degraders Services Chemistry services for targeted protein degraders including PROTAC and related molecular glue degrader modalities. Supports design, synthesis, and characterization of protein degrader conjugates and bifunctional molecules. Targeted at drug developers pursuing targeted protein degradation as a therapeutic modality.
  • Medicinal Chemistry Services Medicinal chemistry services for small molecule drug discovery. Includes analog synthesis, structure-activity relationship (SAR) studies, lead optimization, and custom synthesis to support hit-to-lead and lead optimization campaigns. Targeted at pharmaceutical and biotech researchers pursuing small molecule therapeutics.
  • Custom Synthesis of Small Molecules Custom synthesis of small molecules from milligram to multi-kilogram scale. Includes reference standards, building blocks, intermediates, and bespoke compounds for research and preclinical use. Targeted at pharmaceutical and biotech researchers requiring specialized chemical synthesis not available through standard catalogs.
  • Synthesis of Nucleotides Custom synthesis of nucleotides including phosphoramidite building blocks, modified nucleotides, and oligonucleotide precursors. Supports oligonucleotide therapeutics manufacturing and ADC linker chemistry development. Targeted at developers of oligonucleotide-based drugs and ADC linker chemistries requiring specialized nucleotide inputs.
  • Analytical Services Analytical services for ADCs, small molecules, and large molecules. Includes method development, method validation, release testing, and stability studies supporting discovery through clinical manufacturing. Targeted at biopharmaceutical developers requiring cGMP-compliant analytical characterization of drug substance and drug product.
  • Antibody Production Antibody production services including monoclonal antibody expression, purification, and characterization to support ADC and bioconjugate development programs. Targeted at ADC and bioconjugate developers requiring antibody materials for screening, conjugation, and preclinical evaluation.
  • Cell-Based Functional Assays Cell-based functional assay services including cytotoxicity assays, potency assays, and mechanism-of-action studies. Supports biotherapeutic characterization and ADC efficacy evaluation in vitro. Targeted at biotherapeutic developers requiring functional characterization of antibody and ADC candidates.
  • Combined Payload-Linker Manufacturing Services Integrated payload-linker manufacturing combining payload synthesis and linker conjugation under a single service engagement. Streamlines the supply chain for ADC developers by delivering ready-to-use payload-linker intermediates. Targeted at ADC developers seeking simplified vendor management for payload-linker procurement.

Quantifiable outcome

  • Rapid ADC screening with high-throughput evaluation of 100+ monoclonal antibodies simultaneously
  • +2 more outcomes

Companies that use NJ Bio

Customer profile

Named customers6 records

Segments4 records

Ideal customer profiles4 records

NJ Bio technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature8 records

NJ Bio partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • Ajinomoto Bio-Pharma ServicescoreTechnology or Integration · 31 March 2026Research collaboration to integrate AJICAP site-specific conjugation platform into NJ Bio's ADC discovery and development workflows. Partnership aims to enhance NJ Bio's capabilities in site-specific conjugation, supporting development of targeted therapeutics with emphasis on reducing development risks and improving project outcomes through conjugation precision.
  • L2P Research LabscoreStrategic or Co-development Partner · 6 November 2025Asset purchase and full integration of L2P Research Labs' services to expand NJ Bio's translational research offerings. Acquisition enhances capabilities in preclinical and early-phase clinical research, particularly in oncology, supporting more seamless progression from proof-of-concept to clinic.

Scale indicators7 records

Recent moves7 records

Expansion highlights6 records

NJ Bio competitors and assessment

Company assessment

Direct peers

  • WuXi XDC: WuXi XDC is the leading pure-play ADC CDMO, providing end-to-end antibody, payload-linker and bioconjugation services from discovery through GMP manufacturing. It is the closest direct competitor to NJ Bio in target customers, service scope and ADC specialization.
  • Novasep (Pharma Solutions): Novasep offers CDMO services including highly potent API manufacturing and bioconjugation for ADC clients. Its specialization in cytotoxic payloads and complex chemistry makes it a direct comparator to NJ Bio.
  • Piramal Pharma Solutions: Piramal operates an ADC CDMO business with payload-linker development and GMP manufacturing capacity. It targets the same biopharma and biotech customers with comparable ADC-centric service offerings.
  • Sterling Pharma Solutions: Sterling Pharma Solutions is a CDMO specializing in API development and high-potency manufacturing with growing bioconjugation services. Its focus on complex small molecules and HPAPIs overlaps directly with NJ Bio's payload-linker work.
  • Carbogen Amcis: Carbogen Amcis specializes in highly potent API and payload-linker synthesis with GMP manufacturing, including OEB-5 containment for cytotoxic payloads. Its high-potency focus makes it a direct comparator to NJ Bio's payload-linker capability.

Emerging players

  • Ajinomoto Bio-Pharma Services: Ajinomoto Bio-Pharma Services offers cGMP biologics manufacturing and the AJICAP site-specific conjugation platform, with which NJ Bio has a formal partnership. It is both a potential competitor and partner in the ADC technology space.
  • BioDuro: BioDuro is a CRO/CDMO offering drug discovery, development and manufacturing services including ADC-related chemistry. It serves similar biotech customers but with broader small-molecule emphasis rather than ADC specialization.

Broad incumbents

  • AGC Biologics: AGC Biologics provides biologics CDMO services including bioconjugation and antibody-related manufacturing. It serves biopharma clients at clinical and commercial scale, making it a broad incumbent competitor in the bioconjugate space.
  • Catalent (now part of Novo Holdings): Catalent offers bioconjugation and ADC development services across its global network of GMP facilities. It is a broad incumbent CDMO with overlap on ADC/bioconjugate work but competes from a much larger small-molecule and biologics platform.
  • Lonza (Bioconjugates): Lonza is a global CDMO incumbent with a dedicated bioconjugates business unit offering ADC process development and GMP manufacturing. It competes with NJ Bio in clinical-stage ADC manufacturing but as part of a much broader services portfolio.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

NJ Bio social profiles

Digital presence

NJ Bio compliance and trust

Trust signal

Compliance1 record

NJ Bio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

NJ Bio leadership team

Management profile

Number of profiles

Profiles1 record

NJ Bio funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

NJ Bio M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NJ Bio

What does NJ Bio do?

NJ Bio is an integrated CRO/CDMO providing contract chemistry and biology services for antibody-drug conjugate (ADC), bioconjugate, oligonucleotide, and mRNA development. Its offerings span bioconjugation chemistry, payload-linker design and synthesis, high-throughput antibody screening, GMP clinical manufacturing for Phase I/II trials, bioanalytical characterization, and in vivo/in vitro translational research with oncology xenograft and PDX models. The company delivers these services to biopharmaceutical and biotechnology clients from co-located R&D and GMP facilities in Princeton, NJ and Bristol, PA.

Is NJ Bio a public or private company?

NJ Bio is a private company. It is classified as corporate owned and is currently operating.

When was NJ Bio founded?

NJ Bio was founded in 2019. It employs 101 to 250 people.

Where is NJ Bio based?

NJ Bio is headquartered in Princeton, United States, in the North America region.

How does NJ Bio make money?

Four revenue lines are on record. Contract Research Services (CRO) is the primary driver. The others are contract Manufacturing Services (CDMO), translational Research Services and FTE (Full-Time Equivalent) Models.

Who are NJ Bio's main competitors?

Direct peers on record are WuXi XDC, Novasep (Pharma Solutions), Piramal Pharma Solutions, Sterling Pharma Solutions and Carbogen Amcis. Emerging players are Ajinomoto Bio-Pharma Services and BioDuro. Broad incumbents are AGC Biologics, Catalent (now part of Novo Holdings) and Lonza (Bioconjugates).

Does NJ Bio have an API?

No public API is recorded for NJ Bio.

What industry is NJ Bio in?

NJ Bio's product category is Contract Research and Manufacturing Services (CRO/CDMO) for Biotherapeutics. Its primary akta.pro industry code is HLAGABAC, Biologics (mAbs/Recombinant Proteins) CDMO, with a secondary code of HLAGABAG, Drug Substance–Drug Product Integrated CDMO. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The HinduCohance Lifesciences investing $18 million in NJ Bio, Aruka Bio to sharpen focus on ADCCohance Lifesciences is investing $13 million in NJ Bio and $5 million in Aruka Bio to strengthen its antibody-drug conjugate strategy. The investments, funded from internal accruals, will increase Cohance's NJ Bio stake to 67.3% and give it 65% ownership in Aruka. The moves follow a review of NJ Bio's performance since December 2024.Business StandardCohance to further invest USD 18M to strengthen its ADC strategyCohance announced a $13M investment in NJ Bio and a $5M controlling investment in Aruka Bio, both funded from internal accruals. The deals will raise Cohance's NJ Bio stake to 67.3% and make Aruka a direct subsidiary, with completion expected by September 2026.CNBCTV18Cohance Lifesciences to invest $18 million in NJ Bio, Aruka Bio to deepen ADC push - CNBC TV18Cohance Lifesciences will invest $18 million in NJ Bio and Aruka Bio to deepen its antibody-drug conjugate strategy. The $13 million stake in NJ Bio raises Cohance's ownership to 67.3%, while $5 million in Aruka Bio gives it 65% control. Both deals are expected to close by September.The Times of IndiaCohance Lifesciences to invest USD 18 mn in NJ Bio, Aruka BioCohance Lifesciences announced an $18 million investment, including $13 million in NJ Bio and $5 million in Aruka Bio, to strengthen its antibody-drug conjugate strategy. The investments will raise Cohance's stake in NJ Bio to 67.3% and give it a 65% controlling stake in Aruka Bio, with completion expected by September 2026.NDTV ProfitCohance Lifesciences' 'Weakest Quarter' Prompts Target Price Cut By ICICI SecuritiesCohance Lifesciences reported its weakest quarter in Q1 due to deferred shipments, high costs, and losses at NJ Bio, leading to a significant decline in margins. The company's performance is expected to improve in H2 FY27 with better execution and utilization, with management focusing on commercialization and capacity optimization.Roi-njNJ Bio Inc., Ajinomoto Bio‑Pharma Services agree to collaborate to bolster support for antibody-drug conjugate developmentNJ Bio Inc. and Ajinomoto Bio-Pharma Services announced a research collaboration on March 31 to expand access to AJICAP, Ajinomoto Bio-Pharma's site-specific antibody conjugation platform, for NJ Bio's discovery-stage and early-development clients. The collaboration integrates AJICAP into NJ Bio's workflows, enabling precise chemical modification at defined lysine residues without antibody engineering, improving pharmacokinetics, therapeutic index, and overall developability of antibody-drug conjugates. The companies state the partnership will help reduce development risk, shorten timelines, and improve project outcomes for clients seeking end-to-end support from early drug design through preclinical development.ContractpharmaNJ Bio, Aji Bio‑Pharma Partner to Support ADC DevelopmentNJ Bio, Inc. and Ajinomoto Bio-Pharma Services have entered a research collaboration to expand access to Aji Bio-Pharma's AJICAP site-specific conjugation platform for antibody-drug conjugate (ADC) development. NJ Bio will integrate the AJICAP platform into its discovery and early development workflows, combining its medicinal chemistry, bioconjugation, and biologics expertise with Aji Bio-Pharma's precise, reproducible platform. The collaboration aims to reduce development risk, shorten timelines, and improve project outcomes for NJ Bio's discovery-stage and early development clients.AijournNJ Bio, Inc. and Ajinomoto Bio‑Pharma Services Enter into Collaboration to Strengthen Support for Antibody-Drug Conjugate DevelopmentNJ Bio, Inc. and Ajinomoto Bio-Pharma Services announced a research collaboration to integrate AJICAP™, Aji Bio-Pharma’s site-specific antibody conjugation platform, into NJ Bio’s drug discovery and early development workflows for antibody-drug conjugate (ADC) clients. The AJICAP™ platform enables precise chemical modification at defined lysine residues without antibody engineering, improving pharmacokinetics, therapeutic index, and scalability. The collaboration aims to reduce development risk, shorten timelines, and expand access to next-generation targeted therapeutics for biopharmaceutical companies.PR NewswireNJ Bio, Inc. and Ajinomoto Bio‑Pharma Services Enter into Collaboration to Strengthen Support for Antibody-Drug Conjugate DevelopmentNJ Bio, Inc. and Ajinomoto Bio-Pharma Services announced a research collaboration to expand access to AJICAP™, Aji Bio-Pharma's site-specific conjugation platform for antibody-drug conjugate development. Through this partnership, NJ Bio will integrate the platform into its discovery and development workflows, offering clients precise, reproducible approaches for site-specific payload conjugation to antibodies without requiring antibody engineering. The collaboration is expected to reduce development risk, shorten timelines, and strengthen NJ Bio's position as a comprehensive partner for biopharmaceutical companies seeking end-to-end support from early drug design through preclinical development.PR NewswireNJ Bio, Inc. and Ajinomoto Bio‑Pharma Services Enter into Collaboration to Strengthen Support for Antibody-Drug Conjugate DevelopmentNJ Bio, Inc. and Ajinomoto Bio-Pharma Services announced a research collaboration on April 1, 2026, to expand access to AJICAP, Aji Bio-Pharma's site-specific conjugation platform for antibody-drug conjugate development. Under the agreement, NJ Bio will integrate the AJICAP platform into its discovery and early development workflows, offering clients precise chemical modification at defined lysine residues without antibody engineering. The companies expect the collaboration to reduce development risk, shorten timelines, and strengthen NJ Bio's position as a comprehensive partner for biopharmaceutical companies seeking end-to-end support.